Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%.
Interventions to reduce toxicity are needed.
Short term fasting protects against toxic effects of chemotherapy without decreasing
efficacy. In a prospective clinical trial of breast cancer patients randomized to FMD or
regular diet during chemotherapy, less antiemetic was required in the FMD group; radiographic
and pathologic responses were better in this group.
This trial tests whether platinum-taxane chemotherapy combined with a FMD in advanced and
recurrent ovarian, fallopian tube and primary peritoneal cancer patients is associated with
decreased toxicity and/ or improved tumor response to therapy.